secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001558370-23-015426
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics appoints new President, CMO, CDO; Huber resigns to pursue CEO role
--------------------------------------------------------------------------------

- Martin Huber, M.D., resigns as President and Head of R&D effective Sept 8; remains advisor.
- CEO René Russo adds President title; previously served as President in 2021-2022.
- Katarina Luptakova promoted to CMO; succeeds Huber with 20 years of oncology drug development experience.
- Scott Coleman promoted to CDO; over 25 years in biotech, including at Acceleron and Merck.
- Kevin Brennan enters employment agreement (base $370K, 35% bonus target) as SVP Finance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/xlo-20230830x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer